Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Main Inclusion Criteria: * Written informed consent and HIPAA * Body weight as indicate by a Body Mass Index (BMI) between ≥ 18 and ≤ 28 kg/m², and a body weight \>50 kg * General good health * Ability to use oral inhaler Main Exclusion Criteria: * Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women * Participation in any investigational drug trial within the 30 days before Screening Visit and thereafter * History or current clinically relevant allergies or idiosyncrasy to drugs or food * History of allergic reactions to any corticosteroids including ciclesonide or any excipients of the formulations * Any contraindication to nasally administered corticosteroids * History of a respiratory infection or disorder \[including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)\] within the 30 days before Screening Visit, or development of a respiratory infection during the Screening Period * History or current evidence of any other relevant allergic, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological, psychiatric, or other disease within the last 2 years * Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding Screening Visit